Open AccessMeloxicam inhibits biofilm formation and enhances antimicrobial agents efficacy by Pseudomonas aeruginosa
Author(s) -
She Pengfei,
Wang Yangxia,
Luo Zhen,
Chen Lihua,
Tan Ruichen,
Wang Yanle,
Wu Yong
Publication year - 2018
Publication title -
microbiologyopen
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.881
H-Index - 36
ISSN - 2045-8827
DOI - 10.1002/mbo3.545
Subject(s) - biofilm , pseudomonas aeruginosa , microbiology and biotechnology , tobramycin , meloxicam , antimicrobial , quorum sensing , ciprofloxacin , gentamicin , norfloxacin , chemistry , ofloxacin , antibiotic resistance , antibiotics , pharmacology , biology , bacteria , genetics
Microbial biofilms are communities of surface‐adhered cells enclosed in a matrix of extracellular polymeric substances. Bacterial cells in biofilm are 10~1,000‐fold more resistant to antimicrobials than the planktonic cells. Burgeoning antibiotic resistance in Pseudomonas aeruginosa biofilm has necessitated the development of antimicrobial agents. Here, we have investigated the antibiofilm effect of meloxicam against P. aeruginosa PAO 1 and its potential mechanisms. Further, we have explored whether meloxicam could enhance the susceptibility of bacterial biofilms to treatment with conventional antimicrobials. Here, we found that meloxicam could significantly inhibit PAO 1 biofilm formation in a dose‐dependent manner at the concentration without influence on planktonic cell growth. Meloxicam could also significantly inhibit the motilities, production of extracellular matrix, and expression of quorum sensing‐related genes and virulence factors of PAO 1. Furthermore, synergistic interaction was observed when meloxicam combined with tetracycline, gentamicin, tobramycin, ciprofloxacin, ceftriaxone, ofloxacin, norfloxacin, ceftazidime, and DN ase at subminimal inhibitory concentrations against PAO 1 bioiflm. Collectively, our study lays the foundation for further investigation of repurposing meloxicam as a topical antibiofilm agent to treat P. aeruginosa biofilm‐related infections.